343 related articles for article (PubMed ID: 30534022)
1. The current status of immunotherapy for cervical cancer.
Orbegoso C; Murali K; Banerjee S
Rep Pract Oncol Radiother; 2018; 23(6):580-588. PubMed ID: 30534022
[TBL] [Abstract][Full Text] [Related]
2. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
7. ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer.
Galicia-Carmona T; Arango-Bravo E; Serrano-Olvera JA; Flores-de La Torre C; Cruz-Esquivel I; Villalobos-Valencia R; Morán-Mendoza A; Castro-Eguiluz D; Cetina-Pérez L
Hum Vaccin Immunother; 2021 Aug; 17(8):2617-2625. PubMed ID: 33793380
[TBL] [Abstract][Full Text] [Related]
8. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
Front Immunol; 2018; 9():14. PubMed ID: 29403496
[TBL] [Abstract][Full Text] [Related]
10. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
12. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
Antonia SJ; Vansteenkiste JF; Moon E
Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
[TBL] [Abstract][Full Text] [Related]
16. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
17. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
19. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
20. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Reck M
Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
